We, CellFree Sciences.Co., Ltd. be @ BioJapan 2026
CellFree Sciences Co., Ltd. will exhibit at BioJapan 2026 !
Booth No. B-05 / Yokohama-Kawasaki Pavilion
Booth No. A-63 / Ehime University (Protein Island Matsuyama)
Dates: October 7 (Wed.)–9 (Fri.), 2026, 10:00–17:00
Venue: PACIFICO Yokohama, Exhibition Hall (1-1-1 Minato Mirai, Nishi-ku, Yokohama, Kanagawa 220-0012, Japan)
At the Yokohama-Kawasaki Pavilion (Booth B-05), we will introduce CALICI, a U.S.-based company that provides an AI-driven drug discovery platform based on protein structural information, together with our MaZiQ array platform.
At the Ehime University (Protein Island Matsuyama) booth (A-63), we will showcase our reagents and kits for the wheat germ cell-free protein synthesis system, particularly for difficult-to-express proteins such as membrane proteins. We will also introducenew products designed for the rapid functional evaluation of AI-designed proteins and enzymes engineered through synthetic biology.
In addition, Professor Tatsuya Sawasaki of the Proteo-Science Center, Ehime University, will give a presentation at the Exhibitor Presentation !
Presentation Title:
“Split-Luciferase-Based Protein–Protein Interaction Analysis and Antibody Production Technology Using Rice Seeds”
Date & Time: October 8 (Thu.), 15:00–15:30
Venue: Presentation Stage B
Presentation Overview
Protein–protein interactions (PPIs) are fundamental mechanisms underlying a wide range of biological processes, including intracellular signal transduction, and are important research targets for drug target discovery and elucidation of drug mechanisms of action.
In this presentation, Professor Sawasaki will introduce a new analytical technology that enables simple and highly sensitive detection of PPIs using split luciferase. In addition to conventional PPI analysis, this technology can be applied to the analysis of drug-dependent complex formation induced by targeted protein degradation agents such as molecular glues and PROTACs, as well as to the analysis of target protein ubiquitination.
He will also introduce a novel antibody production technology that uses rice seeds as bioreactors, with the aim of reducing manufacturing costs and ensuring a stable supply of therapeutic antibodies.
The presentation will highlight the potential and future applications of these two innovative technology platforms, spanning drug discovery and evaluation through to biopharmaceutical manufacturing.
We look forward to welcoming you at BioJapan 2026!
CellFree Sciences Co., Ltd.
